📰 Daniel Teper News
Page 3 - Daniel Teper News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daniel Teper. Real-time updates on events, politics, business and more.
April 12, 2021
Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors First-in-class NK Engager multifunctional antibody products can activate patients’ own NK cells or be combined with Cytovia’s off-the-shelf Universal iPSC-derived NK Cells April 12, 2021 11:11 ET | Source: Cytovia Therapeutics Cytovia Therapeutics Miami, Florida, UNITED ...
March 2, 2021
Australia is home to 733 active fintech companies, up from 629 in September 2019, reveals KPMG’s Fintech Landscape 2020 map. This represents an increase of 104 companies that joined the sector between September 2019 and December 2020. The infographic, released on December 21, 2020, provides a snapshot of the Australian fintech ecosystem, revealing several major trends that have emerged over the past year. In particular, the blockchain and cryptocurrency segment saw the strongest growth wit...
February 22, 2021
Shares of Immune Pharmaceuticals Inc (NASDAQ: IMNP) were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company. Shares have given up most of the gains on Thursday trading.... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:
February 16, 2021
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells Cellectis Inc.; Cytovia Therapeutics, Inc. New York, New York, UNITED STATES CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPS...
February 16, 2021
(MENAFN - GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cell...